Aardvark Therapeutics, Inc. Common Stock AARD Cash Flow Statement
| TTM Q1 '26 | TTM Q4 '25 | TTM Q3 '25 | TTM Q2 '25 | TTM Q1 '25 | ||
|---|---|---|---|---|---|---|
| -$69.87M-21.3% | -$57.59M-18.1% | -$48.77M-33.1% | -$36.64M-32.2% | -$27.72M-34.6% | ||
| $42K+16.7% | $36K+5.9% | $34K+6.3% | $32K+68.4% | $19K+18.8% | ||
| $5.72M+44.9% | $3.95M+55.4% | $2.54M+114% | $1.19M+95.9% | $605K+37.8% | ||
| —— | $0— | $0— | $0-100% | $14K-88.0% | ||
| —— | —— | —— | $3.83M+103% | $1.89M+137% | ||
| $3.75M-41.6% | $6.42M+51.2% | $4.24M+21.0% | $3.51M+51.6% | $2.31M+66.6% | ||
| $2.02M-66.7% | $6.04M+1.4% | $5.96M— | —— | —— | ||
| -$3K+40.0% | -$5K+84.4% | -$32K+79.9% | -$159K-30.3% | -$122K+43.8% | ||
| -$390K-15.4% | -$338K-4.6% | -$323K-16.2% | -$278K-24.1% | -$224K-13.1% | ||
| -$61.65M-13.8% | -$54.17M-20.1% | -$45.09M-37.0% | -$32.91M-20.6% | -$27.29M-50.9% | ||
| —— | $95K-5.9% | $101K-1.0% | $102K-1.9% | $104K-4.6% | ||
| —— | —— | —— | —— | $136.54M+1,048% | ||
| $102.25M+27.8% | $80.03M+57.6% | $50.78M+136% | $21.53M+79.0% | $12.03M— | ||
| —— | —— | —— | —— | -$124.62M-939% | ||
| —— | —— | $118K+1.7% | $116K+5.5% | $110K— | ||
| —— | $0-100% | $298.25K-50.0% | $596.5K-33.3% | $894.75K-25.0% | ||
| $449K-99.5% | $89.32M+0.3% | $89.05M+0.1% | $88.94M-48.3% | $171.88M+107% | ||
| —— | —— | —— | —— | —— | ||
| $1.34M+2.8% | $1.31M+11.7% | $1.17M+46.7% | $797K+350% | $177K+84.4% | ||
| -$390K-15.4% | -$338K-4.6% | -$323K-16.2% | -$278K-24.1% | -$224K-13.1% | ||
| $2.02M-66.7% | $6.04M+1.4% | $5.96M— | —— | —— | ||
| $359K-5.5% | $380K-5.5% | $402K+1.0% | $398K+25.6% | $317K+34.9% | ||
| —— | —— | —— | —— | $136.54M+1,048% | ||
| $102.25M+27.8% | $80.03M+57.6% | $50.78M+136% | $21.53M+79.0% | $12.03M— | ||
| —— | —— | —— | $2.39M+3.3% | $2.31M— | ||
| —— | —— | —— | —— | $91.08M— | ||
| -$390K-15.4% | -$338K-4.6% | -$323K-16.2% | -$278K-24.1% | -$224K-13.1% | ||
| —— | $0-100% | $203.75K-50.0% | $407.5K-33.3% | $611.25K-25.0% | ||
| -$3K+40.0% | -$5K+84.4% | -$32K+79.9% | -$159K-30.3% | -$122K+43.8% | ||
| —— | —— | —— | —— | $126.76M— | ||
| —— | $0-100% | $284K-50.0% | $568K-33.3% | $852K-25.0% | ||
| —— | $26K+20.9% | $21.5K+26.5% | $17K+36.0% | $12.5K+56.3% | ||
| —— | -$54.27M-20.1% | -$45.19M-36.9% | -$33.02M-20.5% | -$27.39M-50.5% |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- How much cash does Aardvark Therapeutics, Inc. Common Stock generate?
- Aardvark Therapeutics, Inc. Common Stock (AARD) generated -$61.7M in operating cash flow over the trailing twelve months.
- Where does Aardvark Therapeutics, Inc. Common Stock's cash flow data come from?
- Every line is extracted from Aardvark Therapeutics, Inc. Common Stock's SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.